HROW · Harrow Inc.
AI read · Good for HROW
The AI's read
Harrow released randomized contralateral-eye data showing IHEEZO cut injection discomfort by roughly 58% and was statistically better at every time point. Pain relief matters because patient comfort drives repeat compliance in retina injections. The stock barely moved lower, HROW -1.24% with RSI 33.36, so the market didn't hand this a valuation rerate. The data strengthens the case for adoption and improves the odds for a favorable Phase IV readout later this year. We lean bullish on this idiosyncratic clinical win with 84% confidence, but it is not an instant market-mover that forces a big re-rating. Given the downtrend regime we'd size conservatively and watch commercial uptake and the Phase IV result.